tci Medicare Compliance & Reimbursement - 2017 Issue 23
Industry Notes: Big Pharma VIP Tapped to Head HHS
Subscribe or sign in to view the full article.
Article Overview
This short news item covers a change in leadership at the U.S. Department of Health and Human Services, including the nomination of a former government and pharmaceutical executive and the broader health policy context around the appointment. It is relevant to readers tracking federal health administration, industry-government movement, and policy direction affecting healthcare stakeholders.
Why This Topic Matters
Federal leadership changes can signal shifts in healthcare policy, regulatory priorities, and program direction for providers, payers, manufacturers, and other industry participants.
What You Will Learn
- The background of the nominated HHS leader
- The policy and political context surrounding the nomination
- Why federal health department leadership changes matter to healthcare stakeholders
- When the Senate confirmation process began
Who Should Read This
- Health policy professionals
- Healthcare administrators
- Coding and reimbursement professionals tracking policy news
- Pharmaceutical industry readers
- Payer and provider analysts
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com